SCHEMBL19630056

SCHEMBL19630056

COCCNc1c(C#N)cnc(N)c1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ENPP1 P22413 4/20 0.40
▸ CTSK P43235 1/20 0.37
▸ GAA P10253 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ EGLN2 Q96KS0 2/20 0.36
▸ PIK3CD O00329 1/20 0.36
▸ PIK3CA P42336 1/20 0.36
▸ PIK3CB P42338 1/20 0.36
▸ PIK3CG P48736 1/20 0.36
▸ FGFR4 P22455 1/20 0.36
▸ SRC P12931 3/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ PRKACA P17612 1/20 0.34
▸ PRKACG P22612 1/20 0.34
▸ PRKACB P22694 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29980078 1.00 ENPP1 (0.40) ENPP1CTSKGAAKDM4EALDH1A1
SCHEMBL19781763 0.76 SMN1; SMN2 (0.40) ENPP1CTSKGAAKDM4EALDH1A1
SCHEMBL16668807 0.72 NCF1 (0.46) FGFR4
SCHEMBL19880529 0.71 ALDH1A1 (0.38) ENPP1CTSKGAAKDM4EALDH1A1
SCHEMBL19769046 0.71 CTSK (0.38) ENPP1CTSKGAAKDM4EALDH1A1
SCHEMBL4578984 0.70 CTSK (0.42) CTSKGAAKDM4EALDH1A1HPGD
SCHEMBL13273042 0.70 ALOX5AP (0.41) KDM4EALDH1A1SRCTP53NPC1
SCHEMBL4579364 0.69 SMN1; SMN2 (0.45) CTSKGAAKDM4EALDH1A1HPGD
SCHEMBL25491262 0.69 FGFR4 (0.52) FGFR4
SCHEMBL22096880 0.69 SMN1; SMN2 (0.35) ENPP1CTSKGAAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11667631-B2 FGFR4 inhibitor, preparation method therefor, and applications thereof JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-06-06 — — US disclosed
US-11667631-B2 FGFR4 inhibitor, preparation method therefor, and applications thereof JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-06-06 — — US disclosed
US-20190276451-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2019-09-12 — — US disclosed
US-20190276451-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2019-09-12 — — US disclosed
EP-3444250-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2019-02-20 — — EP disclosed
EP-3444250-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2019-02-20 — — EP disclosed
WO-2017198149-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF 江苏豪森药业集团有限公司 2017-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190276451-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF FGFR4, FGFR1, FGFR2 ENPP1 3652/4885CTSK 3259/4885GAA 2973/4885
US-11667631-B2 FGFR4 inhibitor, preparation method therefor, and applications thereof FGFR4, FGFR1, FGFR2 ENPP1 3652/4885CTSK 3259/4885GAA 2973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback